SureTrader Stock Hero Advertisement SureTrader SPDR Advertisement
Home > Boards > US OTC > Medical - Drugs >

Elite Pharmaceuticals (ELTP)

Add ELTP Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Mocha Jet, Drugdoctor, RizZo, lasers, John_Langston, IB_
Search This Board:
Last Post: 5/24/2015 9:16:07 PM - Followers: 669 - Board type: Free - Posts Today: 72

Elite Pharmaceuticals is a specialty pharmaceutical company specializing in niche generics and committed to the development of abuse-deterrent opioids to help curb diversion, misuse and abuse.  Elite has a pipeline of opioid abuse-deterrent products under development utilizing the company’s proprietary pharmacological abuse-deterrent technology.

Elite’s website can be found by going to

How ART Works:

Elite’s proprietary abuse-deterrent technology, ART™, is a multi-particulate capsule which contains an opioid agonist in addition to naltrexone, an opioid antagonist used primarily in the management of alcohol dependence and opioid dependence. When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases over time providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed or dissolved, the opioid antagonist, naltrexone, is designed to release. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to same receptors in the brain as the opioid agonist and thereby reducing the incentive for abuse or misuse by recreational drug abusers. Elite’s pharmacological approach to abuse-deterrence can be applied to a wide range of opioids used today in pain management.


Recent Press Releases:

Apr 21, 2015
Elite Pharmaceuticals Announces Launch Of Generic Hydroxyzine Tablets

Feb 17, 2015
Elite Pharmaceuticals Provides Guidance On Phase III Study For ELI-200

Jan, 15 2015
Elite Pharmaceuticals Announces First Shipment Of Generic Isradipine Capsules

More information can be found by going to Elite’s investor section:
Highlights From Last Quarter:

Third Quarter ending December 31, 2014
♦  Consolidated revenues for the third quarter of Fiscal 2015 continued their upward trend, rising to $1.4 million, an increase of approximately 8.5% over consolidated revenues for the second quarter of Fiscal 2015. The third quarter revenues for this year were $0.3 million below revenues reported for the third quarter of the prior fiscal year due to a one-time $0.6 million milestone that occurred in the prior year third quarter. Development of our proprietary abuse-deterrent opioid technology continues to be Elite's top priority. During the quarter, Elite invested an additional $2.3 million in clinical trials and other product development activities.

Highlights for the third quarter
♦  As of December 31, our working capital was $8.9 million, including cash of $8.3 million.
♦  Isradipine was recently launched, and we expect to introduce Hydroxyzine and Dantrolene in the near-term.
♦  We're a penny stock company with eyes on NASDAQ; we need to be Sarbanes Oxley compliant. So we are evaluating the gaps that we have by hiring consultants and external consultants in order to evaluate the checks and      balances we have in order for us to get there.
♦  We are creating infrastructure in our facilities with expanding the facilities and adding new equipment and upgrading the current equipment in order to support our (Eli-200) product launch.
2014 was our best year, 2015 will be the year we file our first ART product, and Q1 2016 will be the year we launch our first ART product and hopefully will be the year we will be on NASDAQ.

Nine-Month Period Ending December 31, 2014
♦  Revenues for the nine months ending December 31, 2014 were $3.8 million, an increase of 6% over revenues for the comparable period of the prior year, even with the one-time milestone being included in the prior year revenues. The increase in revenues is due to the continued growth and expansion of Elite's generic product lines.
♦  During the first nine months of the fiscal year, Elite has invested a total of $9.9 million in product development, including successful completion of the human abuse liability study for ELI-200.




President & Chief Executive Officer - Nasrat Hakim

Nasrat Hakim joined Elite in August 2013 as Director, President and Chief Executive Officer. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. Prior to his leading Elite, from 2004 to 2013, Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing 25 sites with more than 3,000 employees under his leadership. Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S., Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development. In 2009, Mr. Hakim founded Mikah Pharma, LLC, a virtual, fully functional pharmaceutical company.

Mr. Hakim’s career started in Medical Laboratory Technology from the Academy of Health and Sciences in the U.S. Army based in San Antonio, TX, followed by Graduate Certification in Regulatory Affairs (RAC) from California State University at Sacramento, Sacramento, CA; Bachelor in Chemistry/Bio-Chemistry and Masters of Science in Chemistry from California State University at Sacramento, Sacramento, CA; and a Masters in Law with Graduate Certification in U.S. Taxation from St. Thomas University, School of Law, Miami, FL.

Board of Directors Chairman - Jerry Treppel

Mr. Treppel is currently a Managing Director of ArcLight Advisors, an investment bank specializing in the health care sector. From October 2008 through March 2013, Mr. Treppel was Managing Director of Ledgemont Capital Group LLC, a boutique merchant bank that provided access to capital and corporate advisory services to public and private companies. Additionally, he served as the managing member of Wheaten Capital Management LLC, a capital management company focusing on investments in the health care sector from 2003 to 2008. Over the past 20 years, Mr. Treppel was an equity research analyst focusing on the specialty pharmaceuticals and generic drug sectors at several investment banking firms including Banc of America Securities, Warburg Dillon Read LLC (now UBS), and Kidder Peabody and Co. He previously served as a healthcare services analyst at various firms, including Merrill Lynch & Co. Mr. Treppel holds a BA in Biology from Rutgers College, an MHA in Health Administration from Washington University, and an MBA in Finance from New York University. Mr. Treppel has been a Chartered Financial Analyst *CFA) since 1988.

Investor Relations:

Vice President of Investor Relations and Corporate - Dianne Will

Dianne Will joined Elite in 2003 as an Investor Relations Specialist and was named Elite’s Vice President of Investor Relations and Corporate Affairs in 2013. In 1996, Ms. Will founded Willstar Consultants, an investor relations consulting firm and has been providing investor relations services to a range of public companies for more than 19 years with a primary focus in the pharmaceutical and tech sectors. Her firm provides corporate services including management and execution of investor relations programs, investor communication, peer research, compliance services, support for
management team changes, proxy fights, crisis management and IPOs.

Investor Relations and Corporate Inquiries

Dianne Will
Vice President of Investor Relations and Corporate Affairs
Telephone: 518-398-6222

Corporate Headquarters

165 Ludlow Avenue
Northvale, New Jersey 07647
Phone: 201-750-2646
Fax: 201-750-2755

Miscellaneous Links:

SEC Filings:

FDA website:

Clinical Trials.Gov:


                                             ELTP Potential Share Price in Relation to Percentage of Pain Market Captured

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ELTP News: Statement of Changes in Beneficial Ownership (4) 05/21/2015 03:03:54 PM
ELTP News: Amended Statement of Changes in Beneficial Ownership (4/a) 05/21/2015 02:43:42 PM
ELTP News: Amended Statement of Changes in Beneficial Ownership (4/a) 05/13/2015 07:53:38 PM
ELTP News: Amended Statement of Changes in Beneficial Ownership (4/a) 05/13/2015 07:38:01 PM
ELTP News: Statement of Changes in Beneficial Ownership (4) 05/13/2015 07:24:17 PM
#154597  Sticky Note Just one of the myriad of reasons Elite Couch 05/23/15 01:16:07 PM
#148487  Sticky Note Ya-don't-say???-Trial-record-1 of-66-for:-eli-200 Drugdoctor 03/21/15 11:04:27 AM
#142585  Sticky Note Great info! This is the beginning of a Dr Speculator Ninja 01/29/15 02:56:03 PM
#142438  Sticky Note FOR THOSE WANTING A DEEPER UNDERSTANDING OF WHY Couch 01/28/15 07:17:31 PM
#106205  Sticky Note Elite’s 1st Generation Triple Patents and their Purpose lasers 04/30/14 08:50:54 AM
#154710   LMAO I agree!!! LMAO John_Langston 05/24/15 09:16:07 PM
#154709   Less than half of a percent of Nasrat's mrwrn2010 05/24/15 09:10:18 PM
#154708   They don't though. And 700k is actually about mrwrn2010 05/24/15 09:07:50 PM
#154707   A big part of the market is not ezey 05/24/15 08:27:22 PM
#154706   Sorry they do and a lot more than John_Langston 05/24/15 08:11:31 PM
#154705   It is still a true statement so all John_Langston 05/24/15 07:42:16 PM
#154704   It won't matter because as I've shown Elite John_Langston 05/24/15 07:32:31 PM
#154703   Nah they don't though, so there's that. mrwrn2010 05/24/15 07:28:08 PM
#154702   execs buying stock as well as taking salary John_Langston 05/24/15 07:23:45 PM
#154701   It's not every day readers catch the subtlety, sharpei 05/24/15 07:20:48 PM
#154700   Jerry Treppel and Nasrat Hakim sank a couple John_Langston 05/24/15 07:17:31 PM
#154699   ARF will just drive people to buy heroine John_Langston 05/24/15 07:11:54 PM
#154698   They all pop once but oh damn ELTP’s John_Langston 05/24/15 07:06:17 PM
#154697   Not sure what "hype" is constantly being referred to. John_Langston 05/24/15 06:58:42 PM
#154696   Last real word is that Elite does not richme 05/24/15 06:55:20 PM
#154695   I just don't think that this is going John_Langston 05/24/15 06:54:44 PM
#154694   Isn't it wonderful that we can take solace Couch 05/24/15 06:51:30 PM
#154693   Investors feel the same way; thankfully ELTP has John_Langston 05/24/15 06:50:36 PM
#154692   So what is the genius part. He richme 05/24/15 06:49:28 PM
#154691   Isn't it wonderful that we can take solace richme 05/24/15 06:46:21 PM
#154690   IF Elite comes back with positive Phase III John_Langston 05/24/15 06:45:38 PM
#154689   Got it; understand completely. Couch 05/24/15 06:42:46 PM
#154688   Writing is on the wall! ELTP execs buying Couch 05/24/15 06:39:26 PM
#154687   What I meant was; we will have to Couch 05/24/15 06:33:32 PM
#154685   Must be that his reasoning is faulty and richme 05/24/15 06:29:23 PM
#154684   *****!!!!! Writing is on the wall! ELTP execs mrwrn2010 05/24/15 06:28:59 PM
#154683   What I meant was; we will have to John_Langston 05/24/15 06:25:33 PM
#154682   Yeah must be why Nasrat hasn't sold one Couch 05/24/15 06:04:18 PM
#154681   Then promptly converted debt before it was due richme 05/24/15 05:52:38 PM
#154678   When the ELTP PPS is 2¢ that may Couch 05/24/15 04:04:06 PM
#154677   You are very welcome, for to keep one's cadillac107 05/24/15 03:59:56 PM
#154676   When the ELTP PPS is 2¢ that may John_Langston 05/24/15 03:35:29 PM
#154673   Jerry Treppel and Nasrat Hakim sank a couple sharpei 05/24/15 01:52:50 PM
#154672   Do you mean "files" as if it already richme 05/24/15 01:51:54 PM
#154671   I didn't mean to say the addicts were richme 05/24/15 01:49:17 PM
#154670   There have been current management errors as well richme 05/24/15 01:45:35 PM
#154669   Like the 16,000 opioid deaths addicts that die Chasing 05/24/15 01:44:22 PM
#154668   Elite is a million / billionaire maker, ELTP richme 05/24/15 01:40:44 PM
#154665   Not sure what "hype" is constantly being referred mrwrn2010 05/24/15 01:34:19 PM
#154662   Maybe the context is being read wrong. richme 05/24/15 01:26:14 PM
#154659   Need to present a balanced picture of what richme 05/24/15 01:11:05 PM
#154657   One must accept this company for what it Couch 05/24/15 12:52:58 PM
#154656   There are many fine, young, and aspiring biotech. cadillac107 05/24/15 12:43:29 PM
#154654   I agree it needs to A) up list Moose45 05/24/15 12:32:57 PM
#154653   I agree with the sentiment, however I feel dr_lowenstein 05/24/15 12:27:33 PM
#154652   One must accept this company for what it cadillac107 05/24/15 12:22:31 PM
#154651   no matter how you spin it, it's been Couch 05/24/15 12:21:30 PM
#154649   I have been hearing the same misinformation since 2011. John_Langston 05/24/15 12:12:48 PM
#154648   Keep your eye on the prize in 2016. Moose45 05/24/15 12:09:34 PM
#154647   no matter how you spin it, it's been Chasing 05/24/15 12:08:02 PM